Develops seralutinib, an inhaled drug candidate for pulmonary hypertension, including pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
10-K for FY2025, filed Mar 17, 2026
Revenue came from Chiesi through a one-time development-cost reimbursement for licenses and ongoing cost-sharing for research and development work; cost-sharing payments were tied to delivery of related services.
10-K for FY2025, filed Mar 17, 2026
10-K for FY2025, filed Mar 17, 2026
FY2025 revenue by product or service ↗$48.5M
10-K for FY2025, filed Mar 17, 2026
$48.5M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Revenue from sale of licenses
Licensed
|
0.0% |
Revenue from sale of licenses, FY2025
$0 Sources
|
Licensed |
|
Revenue from contracts with collaborators
|
100% |
Revenue from contracts with collaborators, FY2025
$48.5M Sources
|
Chiesi contracted with Gossamer as a seralutinib development and commercialization collaborator; the agreement later ended, and Gossamer reacquired worldwide rights.
10-K for FY2025, filed Mar 17, 2026 8-K, filed Jul 27, 2026On May 3, 2024, we, GB002, Inc., our wholly-owned subsidiary, and Gossamer Bio 002 Ltd., our indirect wholly-owned subsidiary, entered into…View ↗
On July 23, 2026, Gossamer Bio, Inc. (the “Company” or “Gossamer”), Gossamer Bio USA, Inc. (formerly GB002, Inc.) and Gossamer Bio 002…View ↗
No. It lost $170.4M in FY2025.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$48.1MView ↗
10-Q for Q3 FY2026, filed Nov 10, 2026
Open tableView ↗
8-K, filed Jul 27, 2026
On July 23, 2026, Gossamer Bio, Inc. (the “Company” or “Gossamer”), Gossamer Bio USA, Inc. (formerly GB002, Inc.) and Gossamer Bio 002…View ↗
A narrower drug pipeline
The older report described drug candidates across immunology, inflammation and oncology, including BTK programs; the latest report centers the business on seralutinib for pulmonary hypertension.
10-K for FY2022, filed Mar 17, 2023 10-K for FY2025, filed Mar 17, 2026We are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the…View ↗
GB5121 (CNS-Penetrant BTK Inhibitor)View ↗
GB7208 is an oral, small molecule, BTK inhibitor in preclinical development for the treatment of multiple sclerosis, or MS. Like GB5121…View ↗
Commercial rights
The older report said Gossamer retained worldwide seralutinib rights; the latest describes Chiesi holding an exclusive license to commercialize seralutinib outside the United States.
10-K for FY2022, filed Mar 17, 2023 10-K for FY2025, filed Mar 17, 2026Seralutinib, also known as GB002, is an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulating…View ↗
In May 2024, we entered into a collaboration agreement with Chiesi. Under the collaboration agreement, we will jointly develop seralutinib…View ↗
Competes with United Therapeutics, Janssen, Liquidia, Merck, Pfizer, Bayer, Gilead Sciences, Pharmosa Biopharma, Cereno Scientific, Insmed, Regeneron, 35Pharma, Novartis, Apollo Therapeutics, AllRock Bio, OrphAI Therapeutics, Pulmovant, ForeSee Pharmaceuticals, and Inhibikase Therapeutics
10-K for FY2025, filed Mar 17, 2026We expect to face competition for seralutinib and RT234 from existing products and products in development. Seralutinib is a PDGFR, CSF1R…View ↗
Loading...